Table 1 Clinical characteristics of fifteen children with juvenile idiopathic arthritis, treated with specific carbohydrate diet for four weeks
Patient ID | Gender | ILAR categorya | Age at onset, years | Age at inclusion, years | Clinical features at inclusion | Treatment during study | ANAb | HLA-B27c |
|---|---|---|---|---|---|---|---|---|
1 | F | Oligo pers | 16.0 | 17.3 | Arthritis, one knee | None | Neg | Pos |
2 | F | ERA | 14.0 | 14.3 | Arthralgia + morning stiffness | NSAID | Neg | Pos |
3 | M | Oligo pers | 2.9 | 9.0 | Arthritis, one knee | None | Pos | nad |
4 | F | Juv psoriatic | 13.6 | 16.7 | Morning stiffness | NSAID | Neg | nad |
5 | F | Poly RF− | 13.6 | 16.5 | Morning stiffness | Methotrexate | Neg | Neg |
6 | F | Oligo ext | 3.0 | 13.8 | Arthritis, one knee + uveitis | Infliximab | Neg | nad |
7 | F | Oligo pers | 3.2 | 11.7 | Pain + stiffness after physical activity, post uveitis | Abatacept + Methotrexate | Neg | nad |
8 | F | Poly RF− | 8.0 | 10.8 | Arthritis, one ankle | Abatacept | Pos | nad |
9 | M | Poly RF− | 13.7 | 17.1 | Arthritis, one ankle, one elbow | Methotrexate | Pos | Neg |
10 | F | Oligo pers | 10.8 | 14.4 | Inflammatory back pain | Etanercept + Methotrexate | Neg | Neg |
11 | F | Oligo pers | 5.6 | 9.5 | Morning stiffness, recurrent joint injections | Methotrexate | Pos | nad |
12 | F | Oligo pers | 3.7 | 11.2 | Joint pain after physical activity, post uveitis | Infliximab Methotrexate | Pos | nad |
13 | M | Oligo pers | 1.5 | 14.6 | Arthritis, one knee | Methotrexate | Neg | Neg |
14 | F | Oligo pers | 5.6 | 6.3 | Morning stiffness, pain | Methotrexate | Neg | nad |
15 | M | ERA | 9.4 | 10.9 | Arthritis, one SIe-joint | None | nad | Pos |